Nasdaq

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025

LNCB74 is undergoing a Phase 1 study, highlighting NextCure's commitment to developing novel cancer therapies. The presentation of trial results at ASCO emphasizes the significance and visibility of ...
Seeking Alpha

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization The study is currently enrolling ...
Nature

B7-H4 Mediated Immune Regulation in Cancer Systems

B7-H4 is a member of the B7 family of immunoregulatory ligands that acts as a potent inhibitory checkpoint within the tumour microenvironment. Unlike PD-L1, its receptor remains unidentified, yet its ...
Nasdaq

NextCure, Inc. Doses First Patient in Phase 1 Study of B7-H4-Targeting Antibody-Drug Conjugate LNCB74

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers. This ...
Yahoo Finance

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast ...

CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...